Our Portfolio

Rivus Pharmaceuticals

Rivus Pharmaceuticals is a leader in mitochondrial biology, is dedicated to improving cardiometabolic health by advancing a new class of medicines called controlled metabolic accelerators (CMAs). Rivus’ lead CMA is the investigational small molecule HU6 in development to treat obesity and associated metabolic diseases, including heart failure with preserved ejection fraction (HFpEF), metabolic dysfunction-associated steatotic liver disease (MASLD) / metabolic dysfunction-associated steatohepatitis (MASH) and Type 2 diabetes.


Bain Capital Healthcare
We have built one of the largest and deepest healthcare investing teams in the world. Click here to read more about the breadth and legacy of our efforts.